Trikafta® (elexacaftor/tezacaftor/ivacaftor; ivacaftor), Symdeko® (tezacaftor/ivacaftor; ivacaftor), Kalydeco® (ivacaftor) – Expanded indication, label updates
December 21, 2020 - Vertex announced the FDA approval of Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor), for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.
Top